Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.70 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.61 |
| ▸ | HTR2B | P41595 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1234889 | 1.00 | KEAP1 (0.70) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 | |
| SCHEMBL2062807 | 1.00 | KEAP1 (0.70) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 | |
| SCHEMBL4741114 | 0.98 | KEAP1 (0.68) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 | |
| SCHEMBL27483674 | 0.98 | KEAP1 (0.68) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 | |
| SCHEMBL1610849 | 0.98 | KEAP1 (0.68) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 | |
| SCHEMBL10842570 | 0.95 | KEAP1 (0.62) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 | |
| SCHEMBL5667254 | 0.84 | ALDH1A1 (0.70) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 | |
| SCHEMBL3913293 | 0.84 | ALDH1A1 (0.70) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 | |
| SCHEMBL403319 | 0.84 | KEAP1 (0.66) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 | |
| SCHEMBL290176 | 0.83 | CHRM2 (0.70) | KEAP1NFE2L2ALDH1A1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-216136708-U | High-vacuum distillation device for alpha-cyclopentyl methyl mandelate | 天津佶品佳化工科技有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-111592491-B | Preparation method of levo-hydrochloric acid demethyl phencynonate | 北京兰晟医药科技有限公司 | 2021-08-17 | — | — | CN | claimed |
| CN-111592491-A | Preparation method of levo-hydrochloric acid demethyl phencynonate | 北京中元恒康生物科技有限公司 | 2020-08-28 | — | — | CN | claimed |
| CN-102190619-B | Novel synthesis method for levorgyration demethyl phencynonate | INST PHARM & TOXICOLOGY AMMS | 2013-07-31 | — | — | CN | claimed |
| CN-103159659-A | Preparation method of muscarinic receptor antagonist glycopyrronium bromide | UNIV SHENYANG PHARMACEUTICAL | 2013-06-19 | — | — | CN | claimed |
| CN-102718654-A | Preparation method of a-cyclopentyl methyl mandelate | BEIJING HEZHONGMING MEDICAL TECHNOLOGY CO LTD | 2012-10-10 | — | — | CN | claimed |
| CN-102190619-A | Novel synthesis method for levorgyration demethyl phencynonate | INST PHARM & TOXICOLOGY AMMS | 2011-09-21 | — | — | CN | claimed |
| US-20250375373-A1 | READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE | AZURITY PHARMACEUTICALS, INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-12383491-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | AZURITY PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12151020-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | SLAYBACK PHARMA LLC (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240189222-A1 | READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE | SLAYBACK PHARMA LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-11938217-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | SLAYBACK PHARMA LLC (US) | 2024-03-26 | — | — | US | disclosed |
| CN-113234003-B | Glycopyrronium bromide and preparation method thereof | 广东嘉博制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-101209993-A | Medical use for levorotatory phencynonate as nerve protecting agent | POISON MED INST PLA MED ACAD (CN) | 2008-07-02 | — | — | CN | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | BODOR LABORATORIES, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007058971-A2 | SOFT ANTICHOLINERGIC ESTERS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058971-A2 | SOFT ANTICHOLINERGIC ESTERS | BODOR NICHOLAS S (US) | 2007-05-24 | — | — | WO | disclosed |
| CN-1781909-A | Process for preparing phencynonate optical isomer | INST OF POISONOUS MEDICINE ACA (CN) | 2006-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12151020-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | CHRNA5, CHRNB4, CHRNB1 | KEAP1 4144/4885NFE2L2 4798/4885ALDH1A1 4812/4885 |
| US-20240189222-A1 | READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE | CHRNA5, CHRNB4, CHRNB1 | KEAP1 4144/4885NFE2L2 4798/4885ALDH1A1 4812/4885 |
| US-20070123557-A1 | side effects reduction; treating an obstructive disease of the respiratory tract or for treating overactive bladder; 3-oxa-9-azatricyclo(3.3.1.0(2,4)nonane derivatives | CHRM2, ADRB1, ADRB2 | KEAP1 1890/4885NFE2L2 2183/4885ALDH1A1 696/4885 |
| US-12383491-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | CHRNA5, CHRNB4, CHRNB1 | KEAP1 4144/4885NFE2L2 4798/4885ALDH1A1 4812/4885 |
| US-20250375373-A1 | READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE | CHRNA5, CHRNB4, CHRNB1 | KEAP1 4144/4885NFE2L2 4798/4885ALDH1A1 4812/4885 |
| US-11938217-B2 | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate | CHRNA5, CHRNB4, CHRNB1 | KEAP1 4144/4885NFE2L2 4798/4885ALDH1A1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.